The effect of Favipiravir on liver enzyme among patients with mild to moderate COVID-19 infection: A prospective cohort study

Main Article Content

Ahmed Hamza Al-Shammari
Mohammed Abd Ali Shahadha

Keywords

ALP, ALT, AST, bilirubin, COVID-19, favipiravir, liver function tests

Abstract

Teratogenicity and hyperuricemia are considered as the major adverse effects of favipiravir, but less is known about other possible side effects which includes drug-induced liver damage and renal injury. In the current research, assessment of favipiravir-induced liver injury was performed by evaluating liver enzymes among patients with mild to moderate COVID-19 infection.A prospective cohort study was conducted on 66 patients diagnosed with mild to moderate COVID-19 infection who were treated with favipiravir for 5 days. During this period, a baseline assessment of liver enzymes (aspartate aminotransferase – AST, ala-nine transaminase – ALT and alkaline phosphatase – ALP) in addition to bilirubin before initiation of ther-apy and after 1 day of completion of therapy were carried out. The comparison of all measured parameters among all patients before and after receiving the treatment showed that non-significant differences were obtained in their levels. It was noticed that COVID-19 patients demonstrated high AST levels in which only 16 patients out of the all-subjected cases (66 patients) had AST levels of less than 45 U/L whereas the major-ity of patients showed normal ALT, ALP, and bilirubin levels. It was concluded that 5 days administration of favipiravir in mild to moderate COVID-19 patients who had no previous liver diseases did not affect the liver enzymes significantly and only transient elevations were occurred.

Abstract 289 | PDF Downloads 253 XML Downloads 134 HTML Downloads 90

References

1.Huang C, Wang Y, Li X, Ren L, et al. Clinical fea-tures of patients infected with 2019 novel corona-virus in Wuhan, China. Lancet (London, England). 2020;395(10223): 497–506. ht t ps://doi.org /10.1016/S0140 - 6736(20)30183-5
2.Chen N, Zhou M, Dong X, Qu J, et al.Epidemiological and clinical characteristics of99 cases of 2019 novel coronavirus pneumoniain Wuhan, China: a descriptive study.Lancet(London, England).2020;395(10223):507–13.https://doi.org/10.1016/S0140-6736(20)30211-7
3.Liu J, Shu YL, Zhou XN. Transmission patternsand control of COVID-19 epidemic. Indian JPlantPhysiol. 2020;9:112.
4.Rothe C, Schunk M, Sothmann P, Bretzel G,etal. Transmission of 2019-nCoV infection froman asymptomatic contact in Germany.N Engl JMed.2020;382(10):970–1. ht t ps://doi.org /10.1056/N EJ Mc20 01468
5.Singhal T. A review of coronavirus disease-2019(COVID -19).Indian J Pediatr.2020;87(4):281– 6.https://doi.org/10.1007/s12098-020-03263-6
6.Pei G, Zhang Z, Peng J, Liu L, et al. Renal involve-ment and early prognosis in patients with COVID-19 pneumonia.JASN.2020;31(6):1157–65. htt ps://doi.org/10.1681/ASN.2020030276
7.Cai Q, Huang D, Yu H, Zhu Z, et al. COVID-19: Abnormal liver function tests.J Hepatol.2020;73(3):566–74. ht t ps://doi.org /10.1016/j.jhep.2020.04.006
8.Mohammed AA, Mustafa MN, Abdulsattar SA,Al-zaid, AS. COVID 19: Evaluate of liver andrenal function tests in Iraqi patients. Medico-legalupdate. 2021;21(1):7–10. https://doi.org/10.37506/mlu.v21i1.2268
9.Ozma MA, Maroufi P, Khodadadi E, Köse Ş, et al.Clinical manifestation, diagnosis, prevention andcontrol of SARS-CoV-2 (COVID-19) during theoutbreak period. Infez Med. 2020;28(2):153–65.PM I D: 32275257.
10.Humar A, McGilvray I, Phillips MJ, Levy GA.Severe acute respiratory syndrome and the liver.Hepatology. 2004;39:291– 4. ht t ps://doi.org /10.1002/hep.20069
11.Chan HL, Leung WK, To KF, Chan PK.Retrospective analysis of liver function derange-ment in severe acute respiratory syndrome. Am JMed. 2004;116(8):566–7. ht t ps://doi.org /10.1016/j.amjmed.2003.11.024
12.Du YX, Chen XP. Favipiravir: Pharmacokineticsand concerns about clinical trials for 2019-nCoVinfection. Clin Pharmacol Ther. 2020;108(2):242–7. ht t ps://doi.org /10.1002/cpt.1844
13.Nagata T, Lefor AK, Hasegawa M, Ishii M.Favipiravir: Anew medication for the Ebola virusdisease pandemic. Disaster Med Public Health Prep.2015;9(1):79 –81. ht t ps://doi.org /10.1017/d mp.2014.151
14.Nguyen TH, Guedj J, Anglaret X, Laouénan C.Favipiravir pharmacokinetics in ebola-infectedpatients of the JIKI trial reveals concentra-tions lower than targeted. PLoS Negl Trop Dis.2017;11(2):e0005389. https://doi.org/10.1371/jour-nal.pntd.0005389
15.Furuta Y, Komeno T, Nakamura T. Favipiravir(T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449 – 63. https://doi.org/10.2183/pjab.93.027
16.Yamazaki S, Suzuki T, Sayama M, NakadaTA.Suspected cholestatic liver injury inducedby favipiravir in a patient with COVID-19. JInfect Chemother. 2021;27(2):390–2. htt ps://doi.org/10.1016/j.jiac.2020.12.021
17.Bertolini A, van de Peppel IP, Bodewes FAJA,Moshage H. abnormal liver function tests inpatients with COVID-19: Relevance and potentialpathogenesis. Hepatology. 2020;72(5):1864–72.ht t ps://doi.org /10.1002/ hep.31480
18.Kumar A, Kumar P, Dungdung A, Kumar GuptaA. Pattern of liver function and clinical profile inCOVID-19: A cross-sectional study of 91 patients.Diabetes Metab Syndr. 2020;14(6):1951–4. htt ps://doi.org/10.1016/j.dsx.2020.10.001
19.Çetin Kargin N. The effect of smoking on COVID-19-linked biomarkers in hospitalized patients withCOVID-19. J Clin Lab Anal. 2021;35(10):e23983.https://doi.org/10.1002/jcla.23983
20.Hassanipour S, Arab-Zozani M, Amani B,Heidarzad F. The efficacy and safety of Favipiravirin treatment of COVID-19: A systematic reviewand meta-analysis of clinical trials. Sci Rep.2021;11(1):11022. ht t ps://doi.org /10.1038/s41598-021-90551- 6
21.Udwadia ZF, Singh P, Barkate H, Patil S. Efficacyand safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71. ht t ps://doi.org /10.1016/j.ijid.2020.11.142
22.Khamis F, Al Naabi H, Al Lawati A, AmbusaidiZ.Randomized controlled open label trial on the useof favipiravir combined with inhaled interferonbeta-1b in hospitalized patients with moderate tosevere COVID-19 pneumonia. Int J Infect Dis.2021;102:538–43. ht t ps://doi.org /10.1016/j.ijid.2020.11.0 0 8
23.Erdem HA, Korkma PE, Çağlayan D, IşıkgözTaşbakan M. Treatment of SARS-CoV-2 pneu-monia with favipiravir: Early results from theEge University cohort, Turkey. Turk J Med Sci.2021;51(3):912 –20. https://doi.org/10.3906/sag-2008-33
24.Kumar P, Kulkarni A, Sharma M, Rao PN.Favipiravir-induced liver injury in patientswith coronavirus disease 2019. J Clin TranslHepatol. 2021;9(2):276–8. https://doi.org/10.14218/JCTH.2021.00011
25.Hwaiz R, Merza M, Hamad B, HamaSalih S.Evaluation of hepatic enzymes activities inCOVID-19 patients. Int Immunopharmacol.2021;97:107701. https://doi.org/10.1016/j.intimp.2021.107701

Most read articles by the same author(s)